Detection of Markers of Hepatitis Viral Infection in the Tissue of Bile Duct Carcinoma
Liu Hou-Bao,Qian Zhen-Yu,Wang Bing-Sheng,Tong Sai-Xiong
DOI: https://doi.org/10.1097/00029330-200806020-00022
2008-01-01
Abstract:Hepatitis B virus (HBV) is an admitted oncogenic virus. Many epidemiological and molecular biological studies have demonstrated that chronic infection with HBV is a major risk factor associated with the development of hepatocellular carcinoma (HCC) and intrahepatic bile duct cancer.1-4 Compared with hepatocytes and intrahepatic bile duct epithelial cells, extrahepatic bile duct epithelial cells have autoploid in embryogenesis, continuity in anatomy and a similar internal environment. The question arises whether extrahepatic bile duct epithelial cells can receive HBV infection or not? The role of hepatitis viral infection in the pathogenesis of bile duct carcinoma has not yet been clarified, although a causative relationship between HBV or HCV infection and extrahepatic bile duct carcinoma has been reported in the literature.5,6 In this study, we focused on the evidence of hepatitis viral infection in tissue of bile duct carcinoma. METHODS General data Cholangiocarcinoma group: 25 newly diagnosed bile duct carcinoma patients who were consequently hospitalized were enrolled in this study. Location of the carcinoma was 19 in the upper part, 1 in the upper-middle part, 2 in the middle and 3 in the lower part of the extrahepatic bile duct; 17 male patients, 8 female patients; aged 31-73 years, mean age of 61 years. No case had a history of HBV vaccine inoculation, 3 patients had a history of hepatitis B and 1 had a history of hepatitis A. Control group: 77 concurrent patients with benign biliary tract diseases (choledocholethiasis or cyst of the common bile duct) acted as controls, 40 male patients, 47 female patients, mean age of 64 years. Detection of HBV marker in serum before operation ELISA was applied to detect serum anti-HBe, anti-HBc and anti-HCV, electrochemoluminescent immunoassay to detect serum HBsAg, anti-HBs and HBeAg in 25 patients of bile duct carcinoma and 20 patients of benign bile duct disease as a control. Detection of HBV genes and DNA Carcinoma, bile duct and liver tissue specimens in the cancer group and control group were taken during operations to detect HBsAg, HBcAg, HBxAg and CP10 by immunohistochemical staining, HBV S gene and X gene by PCR-EB and HBV DNA by in situ hybridization. Statistical analysis The data demonstrated the frequency and percentage, and a group comparison was made using a chi-square test and SPSS software. A P value less than 0.05 was considered statistically significant. RESULTS Detection of HBV marker in serum The positive rates of serum HBsAg, anti-HBs, anti-HBe and anti-HBc were 40% (10/25), 24% (6/25), 32% (8/25) and 40% (10/25) respectively, with an overall HBV infection rate of 72% (18/25) in the cancer group. The above markers were 4% (3/77), 16% (12/77), 1% (1/77) and 1% (1/77) respectively, with an overall HBV infection rate of 21% (16/77) in the controls. There was significant difference in the overall HBV infection rate (P <0.001). In the cancer group, the serum anti-HCV positive rate was only 4%. Detection of HBV genes and DNA In the 25 cases of bile duct carcinoma, positive rates of HBsAg, HBcAg, HbxAg and CP10 in tumour tissue were 52% (13/25), 4% (1/25), 71% (17/24) and 48% (12/25) respectively, and 88% (14/16), 0, 60% (9/15) and 44% (7/16) in liver tissue. In 20 benign biliary tract diseases, positive rates of the above antigens were respectively 20% (4/20), 0, 5% (1/20) and 11% (2/19) in bile duct tissue and 42% (8/19), 0, 26% (5/19) and 11% (2/19) in liver tissue. The difference between the two groups was statistically significant (P <0.05). In the 20 cancer patients, passive rates for the HBV S gene and X gene in carcinoma tissue were respectively 7 (35%) and 8 patients (40%), but were identical in liver tissue, i.e. 47% (8/17). In the 20 controls, the HBV S gene and X gene in bile duct tissue were positive in 3 (15%) and 5 patients (25%), with 5 patients (25%) positive in liver tissue. Differences in the positive rates of HBV S gene and X gene had no statistical significance (P >0.05). In patients with HBsAg positive immunohistochemical staining liver cells, HBV DNA was detected by an in situ hybridization technique in 11 patients with bile duct carcinoma and 7 controls. In tumour and liver tissue of cancer patients, 6 (55%) and 7 patients (64%) were positive for HBV DNA respectively, while positive rates were achieved for 3 (43%) and 4 patients (57%) in bile duct and liver tissue in the controls. The positive HBV DNA signals congregated mass-like and were located only in the nuclei. DISCUSSION HBV and HCV infection has been reported to be associated with the development of hepatocellular and intrahepatic cholangiocarcinoma. Whether the bile duct epithelium is susceptible to hepatitis viral infection and whether there is statistical difference in hepatitis viral infection rates between patients with bile duct carcinoma and benign biliary tract diseases, is one of the problems that need to be investigated. Consequently, we have focused on evidence of hepatitis viral infection in bile duct carcinoma tissue. Our findings demonstrated that the overall HBV infection rate in patients with bile duct carcinoma was 72%. It is significantly higher than in patients with benign biliary tract diseases. The results suggest that past infection or persistent infection with HBV may be an aetiological factor of bile duct carcinoma. The existence of hepatitis viral antigens in bile duct carcinoma cells is direct evidence of hepatitis viral infection. The positive rates of HBsAg, HBxAg and CP10 in cholangiocarcinoma and liver tissue were significantly higher in the cancer group than in the control group. In total, 71% patients with bile duct carcinoma were HBxAg positive in their carcinoma cells. In addition, CP10 positive staining was also observed in 48%. Although all 5 markers of HBV infection were negative in the serum specimens of some patients with cholangiocarcinoma, HBsAg antigens were still detected in their tumour or liver tissue. The overall rates of HBV infection reached 94% in the cancer group. The results suggest that there exists a close relationship between bile duct carcinoma and HBV infection in the majority of patients, and in nearly half of them, there is an overlapping infection of both HBV and HCV. We also found that the HBV S gene and X gene were present in bile duct carcinoma tissue and HBV DNA existed in the nuclei of bile duct carcinoma cells. Numerous studies have proven that HBxAg and HCV core protein may play one or more important roles in hepatocellular carcinogenesis. Integration of HBV DNA into the genome of host cells can start or promote malignant transformation of cells by several pathways, such as insertion mutation, rearrangement of chromosomes, etc. The products of the integrated viral DNA fragments, such as HBxAg polypeptide, contribute in an important way to hepatocellular carcinogenesis in transgene mice. HCV gene products have a function of gene regulation to modulate cell growth and differentiation, and are involved in the malignant transformation of HCV-infected cells.7-9 However, the detailed carcinogenic mechanisms have not been elucidated completely, so further research is necessary to clarify the role of HBV or HCV in the development of bile duct carcinoma.